new BindingDB logo
myBDB logout

30 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
23777782 107 Orally available and efficaciousa41/a47 integrin inhibitors.EBI Elan Pharmaceuticals
23562062 4 Arylsulfonamide pyrimidines as VLA-4 antagonists.EBI Elan Pharmaceuticals, Inc.
23312474 36 Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.EBI Hoffmann-La Roche Inc.
23312471 31 Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual actinga4ß1 anda4ß7 receptor antagonists.EBI Hoffmann-La Roche Inc.
18331794 20 Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.EBI Millennium Pharmaceuticals
18226905 60 Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists.EBI Johnson& Johnson Pharmaceutical Research& Development
12139455 78 Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.EBI Genentech Inc.
17118652 15 Highly constrained bicyclic VLA-4 antagonists.EBI Merck Research Laboratories
15081035 24 Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.EBI Merck Research Laboratories
15081033 21 Amidines as amide bond replacements in VLA-4 antagonists.EBI Merck Research Laboratories
14667228 3 Synthesis and structure-activity relationship of mannose-based peptidomimetics selectively blocking integrin alpha4beta7 binding to mucosal addressin cell adhesion molecule-1.EBI Technische Universität München
12617914 116 N-(3-phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists.EBI Merck Research Laboratories
12270174 34 Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores.EBI Genentech
12127538 26 N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.EBI Merck Research Laboratories
12127523 22 N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.EBI Merck Research Laboratories
12031329 110 Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.EBI Merck Research Laboratories
11844689 51 Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.EBI Merck Research Laboratories
11755344 47 The discovery of small molecule carbamates as potent dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.EBI Merck Research Laboratories
11755338 24 Specific and dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) integrins.EBI Merck Research Laboratories
11677134 42 Design and synthesis of potent and selective inhibitors of integrin VLA-4.EBI Novartis Institute for Biomedical Research
11591507 79 The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.EBI Merck Research Laboratories
11472212 6 Design and synthesis of potent and selective alpha(4)beta(7) integrin antagonists.EBI Technische Universität München
10915035 16 Cell adhesion antagonists: synthesis and evaluation of a novel series of phenylalanine based inhibitors.EBI Millennium Pharmaceutical
10853677 34 Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.EBI Celltech Chiroscience
10072689 39 Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.EBI Biogen Inc.
16495061 8 Selection of a 2-azabicyclo[2.2.2]octane-based alpha4beta1 integrin antagonist as an inhaled anti-asthmatic agent.BDB Johnson & Johnson Pharmaceutical
16112583 74 Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists.BDB Johnson & Johnson Pharmaceutical
16722660 60 Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.BDB Johnson & Johnson Pharmaceutical